Shots:
Astellas has partnered with Vir Biotechnology to advance VIR-5500, a PRO-XTENÂ dual-masked CD3 T-cell engager targeting PSMA, for the treatment of prostate cancer
As per the deal, Astellas will fund 60% & Vir 40% of global development costs; Vir will continue the P-I trial until transition, after which Astellas will assume development. Also, Vir will…
